ProKidneyPROK
About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
Employees: 163
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
290% more call options, than puts
Call options by funds: $1.18M | Put options by funds: $303K
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
72% more capital invested
Capital invested by funds: $78M [Q1] → $134M (+$56.3M) [Q2]
18% more funds holding
Funds holding: 55 [Q1] → 65 (+10) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
24.38% less ownership
Funds ownership: 70.77% [Q1] → 46.39% (-24.38%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Guggenheim Vamil Divan 75% 1-year accuracy 12 / 16 met price target | 200%upside $6 | Buy Initiated | 10 Sept 2024 |
B of A Securities Jason Gerberry 44% 1-year accuracy 11 / 25 met price target | 50%upside $3 | Neutral Maintained | 4 Sept 2024 |